Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoSil MedicalASX:OSL -1.79%48 Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus rates ASX:OSL with a GF Score™ of 48/100 and a GF Value™ of A$2.90 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 313 Medical Devices & Instruments companies, OncoSil Medical ranks worse than 319488.5% on this metric.
As of today (2026-07-14), the Forward Annual Dividend Yield of OncoSil Medical is 0.00%.
As of today (2026-07-14), the Trailing Annual Dividend Yield of OncoSil Medical is 0.00%.
ASX:OSL's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.07 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
OncoSil Medical (ASX:OSL) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
OncoSil Medical Forward Dividend Yield % Related Terms
ASX:OSL vs ABT, SYK, MDT: Forward Dividend Yield % Comparison
For the Medical Devices subindustry, OncoSil Medical's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical Forward Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
OncoSil Medical (ASX:OSL) has a Forward Dividend Yield % of 0.00% as of Jul. 14, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on OncoSil Medical and its competitors. According to the industry distribution chart, OncoSil Medical ranks #999999 out of 313 companies in the Medical Devices & Instruments industry.
Is OncoSil Medical's Forward Dividend Yield % too high?
OncoSil Medical's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, OncoSil Medical ranks #999999 out of 313 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, OncoSil Medical has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Forward Dividend Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #999999 out of 313 companies for Forward Dividend Yield %. This places OncoSil Medical in the lower half of its industry. The industry median Forward Dividend Yield % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.07, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on OncoSil Medical and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.90, compared to a current price of A$1.38 — trading 52.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. OncoSil Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.38 is trading 52.6% below its estimated GF Value™ of A$2.90.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
Forward Dividend Yield %: 0.00%
GF Value™: A$2.90 vs. price of A$1.38 (52.6% below fair value)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
48GF Score
Get the complete analysis for ASX:OSL
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
